Personalising Treatment for High-Grade Serous Ovarian Carcinoma

被引：18

作者：

Cojocaru, E. ^{[1
]}

Parkinson, C. A. ^{[1
,2
]}

Brenton, J. D. ^{[1
,2
]}

机构：

[1] Cambridge Univ Hosp, Dept Oncol, Cambridge, England

[2] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England

来源：

CLINICAL ONCOLOGY | 2018年 / 30卷 / 08期

关键词：

Genomics; high-grade serous ovarian cancer; PARP inhibitors; RECURRENT EPITHELIAL OVARIAN; PHASE-III TRIAL; OLAPARIB MAINTENANCE THERAPY; CIRCULATING TUMOR DNA; DOUBLE-BLIND; OPEN-LABEL; INTRAPERITONEAL CISPLATIN; FALLOPIAN-TUBE; ONCOLOGY-GROUP; PROGNOSTIC-SIGNIFICANCE;

D O I：

10.1016/j.clon.2018.05.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is a heterogeneous group of cancers that differ by cell of origin and genomic features. High-grade serous ovarian cancer (HGSOC) is the commonest histiotype and is characterized by extreme genomic complexity and dysregulation of DNA damage repair pathways, particularly homologous recombination deficiency. New insights from molecular profiling into homologous recombination deficiency now offers the credible possibility of personalizing treatment choices for women with HGSOC using poly(ADP-ribose) polymerase inhibitor (PARP) therapy. Although the presence of tumour infiltrating lymphocytes (TILs) in the microenvironment is associated with improved survival in HGSOC, the role of anti-angiogenic and immune checkpoint inhibitor therapy remains unclear. PARP inhibition combined with immunotherapy is an exciting combination strategy for future therapeutic development for women with advanced HGSOC. (C) 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

引用

页码：515 / 524

页数：10

共 92 条

[71] Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial [J].

Pujade-Lauraine, Eric ;

Hilpert, Felix ;

Weber, Beatrice ;

Reuss, Alexander ;

Poveda, Andres ;

Kristensen, Gunnar ;

Sorio, Roberto ;

Vergote, Ignace ;

Witteveen, Petronella ;

Bamias, Aristotelis ;

Pereira, Deolinda ;

Wimberger, Pauline ;

Oaknin, Ana ;

Mirza, Mansoor Raza ;

Follana, Philippe ;

Bollag, David ;

Ray-Coquard, Isabelle .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) :1302-+

[72] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer [J].

Reck, Martin ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Leiby, Melanie A. ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Rangwala, Reshma ;

Brahmer, Julie R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1823-1833

[73] Pembrolizumab versus Ipilimumab in Advanced Melanoma [J].

Robert, Caroline ;

Schachter, Jacob ;

Long, Georgina V. ;

Arance, Ana ;

Grob, Jean Jacques ;

Mortier, Laurent ;

Daud, Adil ;

Carlino, Matteo S. ;

McNeil, Catriona ;

Lotem, Michal ;

Larkin, James ;

Lorigan, Paul ;

Neyns, Bart ;

Blank, Christian U. ;

Hamid, Omid ;

Mateus, Christine ;

Shapira-Frommer, Ronnie ;

Kosh, Michele ;

Zhou, Honghong ;

Ibrahim, Nageatte ;

Ebbinghaus, Scot ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) :2521-2532

[74] Beyond DNA repair, the immunological role of PARP-1 and its siblings [J].

Rosado, Maria Manuela ;

Bennici, Elisabetta ;

Novelli, Flavia ;

Pioli, Claudio .

IMMUNOLOGY, 2013, 139 (04) :428-437

[75] Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers [J].

Sakai, Wataru ;

Swisher, Elizabeth M. ;

Karlan, Beth Y. ;

Agarwal, Mukesh K. ;

Higgins, Jake ;

Friedman, Cynthia ;

Villegas, Emily ;

Jacquemont, Celine ;

Farrugia, Daniel J. ;

Couch, Fergus J. ;

Urban, Nicole ;

Taniguchi, Toshiyasu .

NATURE, 2008, 451 (7182) :1116-U9

[76] Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma [J].

Sakai, Wataru ;

Swisher, Elizabeth M. ;

Jacquemont, Celine ;

Chandramohan, Kurapaty Venkatapoorna ;

Couch, Fergus J. ;

Langdon, Simon P. ;

Wurz, Kaitlyn ;

Higgins, Jake ;

Villegas, Emily ;

Taniguchi, Toshiyasu .

CANCER RESEARCH, 2009, 69 (16) :6381-6386

[77] Neoantigens in cancer immunotherapy [J].

Schumacher, Ton N. ;

Schreiber, Robert D. .

SCIENCE, 2015, 348 (6230) :69-74

[78] Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis [J].

Schwarz, Roland F. ;

Ng, Charlotte K. Y. ;

Cooke, Susanna L. ;

Newman, Scott ;

Temple, Jillian ;

Piskorz, Anna M. ;

Gale, Davina ;

Sayal, Karen ;

Murtaza, Muhammed ;

Baldwin, Peter J. ;

Rosenfeld, Nitzan ;

Earl, Helena M. ;

Sala, Evis ;

Jimenez-Linan, Mercedes ;

Parkinson, Christine A. ;

Markowetz, Florian ;

Brenton, James D. .

PLOS MEDICINE, 2015, 12 (02)

[79] Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis [J].

Shang, Bin ;

Liu, Yao ;

Jiang, Shu-juan ;

Liu, Yi .

SCIENTIFIC REPORTS, 2015, 5

[80] Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access [J].

Shipman, Hannah ;

Flynn, Samantha ;

MacDonald-Smith, Carey F. ;

Brenton, James ;

Crawford, Robin ;

Tischkowitz, Marc ;

Hulbert-Williams, Nicholas J. .

JOURNAL OF GENETIC COUNSELING, 2017, 26 (06) :1280-1291

← 1 2 3 4 5 6 7 8 9 10 →